{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:06:50Z","timestamp":1755036410078},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T00:00:00Z","timestamp":1446595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0141931","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T19:11:37Z","timestamp":1446664297000},"page":"e0141931","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study"],"prefix":"10.1371","volume":"10","author":[{"given":"Takeshi","family":"Nishijima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunefusa","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,11,4]]},"reference":[{"key":"ref1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf<\/ext-link> (18 December 2013, date last accessed)."},{"key":"ref2","unstructured":"World Health Organization. Consolicated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Invection: Recommendations for a Public Health Approach. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/85321\/1\/9789241505727_eng.pdf\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/85321\/1\/9789241505727_eng.pdf<\/ext-link>. (19 January 2014, date last accessed)."},{"key":"ref3","article-title":"Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients with Lamivudine-resistant Chronic Hepatitis B","author":"S Fung","year":"2013","journal-title":"Gastroenterology"},{"key":"ref4","unstructured":"Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization. July 2014 Available at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/pub\/guidelines\/keypopulations\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/pub\/guidelines\/keypopulations\/en\/<\/ext-link> Accessed 19 February 2015."},{"key":"ref5","unstructured":"Preexposure Prophylaxis for the Prevention of HIV Infection in the United States 2014 Clinical Practice Guideline. American Center for Disease Prevention and Control. Available at:<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cdc.gov\/hiv\/pdf\/PrEPguidelines2014.pdf\" xlink:type=\"simple\">http:\/\/www.cdc.gov\/hiv\/pdf\/PrEPguidelines2014.pdf<\/ext-link>. Accessed 19 February 2015."},{"key":"ref6","first-page":"248","article-title":"The role of drug transporters in the kidney: lessons from tenofovir","volume":"5","author":"DM Moss","year":"2014","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1053\/ajkd.2002.36924","article-title":"Fanconi syndrome and renal failure induced by tenofovir: a first case report","volume":"40","author":"D Verhelst","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283112b8e","article-title":"The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients","volume":"22","author":"JE Gallant","year":"2008","journal-title":"AIDS"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e29977","DOI":"10.1371\/journal.pone.0029977","article-title":"Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection","volume":"7","author":"T Nishijima","year":"2012","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/labinvest.2009.14","article-title":"Tenofovir renal toxicity targets mitochondria of renal proximal tubules","volume":"89","author":"JJ Kohler","year":"2009","journal-title":"Lab Invest"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/508546","article-title":"Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy","volume":"194","author":"H Izzedine","year":"2006","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/QAI.0b013e31815e7478","article-title":"Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients","volume":"47","author":"JJ Kiser","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/598507","article-title":"Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study","volume":"48","author":"S Rodriguez-Novoa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/infdis\/jir215","article-title":"Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction","volume":"204","author":"SP Pushpakom","year":"2011","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2217\/pgs.09.115","article-title":"Pharmacogenetics of tenofovir treatment","volume":"10","author":"S Rodriguez-Novoa","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/cis772","article-title":"Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study","volume":"55","author":"T Nishijima","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.ki.5002541","article-title":"The impact of HIV on chronic kidney disease outcomes","volume":"72","author":"AI Choi","year":"2007","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/QAD.0b013e32834957da","article-title":"Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir","volume":"25","author":"A Brennan","year":"2011","journal-title":"AIDS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"S Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s10157-012-0704-5","article-title":"Performance of GFR equations in Japanese subjects","volume":"17","author":"M Horio","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1097\/QAD.0000000000000347","article-title":"Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight","volume":"28","author":"T Nishijima","year":"2014","journal-title":"AIDS"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"197","author":"M Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years","volume":"21","author":"MR Nelson","year":"2007","journal-title":"AIDS"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1089\/aid.2006.22.744","article-title":"Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate","volume":"22","author":"H Gatanaga","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1093\/cid\/ciu617","article-title":"Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"59","author":"GM Lucas","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1067\/mcp.2002.126177","article-title":"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein","volume":"72","author":"Y Kurata","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAD.0000000000000112","article-title":"Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta","volume":"28","author":"Z Neumanova","year":"2014","journal-title":"AIDS"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.amjcard.2012.12.045","article-title":"Renal impairment in a &quot;real-life&quot; cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding)","volume":"111","author":"V Roldan","year":"2013","journal-title":"Am J Cardiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/157016210793499259","article-title":"Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight","volume":"8","author":"K Chaisiri","year":"2010","journal-title":"Curr HIV Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e22661","DOI":"10.1371\/journal.pone.0022661","article-title":"Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients","volume":"6","author":"T Nishijima","year":"2011","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients","volume":"24","author":"A Mocroft","year":"2010","journal-title":"AIDS"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates","volume":"56","author":"M Horio","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/jac\/dku129","article-title":"ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen","volume":"69","author":"W Manosuthi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/QAI.0000000000000504","article-title":"No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults","volume":"68","author":"W Sirirungsi","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"AS Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref37","article-title":"Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America","author":"GM Lucas","year":"2014","journal-title":"Clinical Infectious Diseases"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir","volume":"43","author":"BP Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study","volume":"207","author":"L Ryom","year":"2013","journal-title":"J Infect Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0b013e31827ce4ee","article-title":"Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration","volume":"62","author":"I Poizot-Martin","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.clpt.6100269","article-title":"The effect of lopinavir\/ritonavir on the renal clearance of tenofovir in HIV-infected patients","volume":"83","author":"JJ Kiser","year":"2008","journal-title":"Clin Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0141931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T16:39:01Z","timestamp":1540312741000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0141931"}},"subtitle":[],"editor":[{"given":"Roger","family":"Le Grand","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,4]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0141931","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,4]]}}}